| Title: | Polish Pharmaceutical Report |
| Price: | $375.00 |
| Publication Date: | May 07, 2008 |
| Source: | IntelliNews |
| Abstract: | Poland's pharmaceutical market is to grow steadily within the next few years and eventually is to reach PLN 38bn in 2015. Such a growth comes in line with global market trends of ageing population and growing costs of innovative medicines. Market researcher IMS Health forecasts that this year sales of drugs are to reach PLN 17bn or 6.2% (PLN 992mn) up compared to last year. For the next five years, the market is to achieve annual average growth of 6.26%. Other agencies also published optimistic forecasts for the growth of the pharmaceutical market. The Economist Intelligence Unit (EIU) estimates that sales of drugs in Poland are to go up to USD 5.95bn in 2008 and to USD 8.0bn in 2012. And Datamonitor says that the value of the market is to go up to USD 7.4bn in 2012. Meanwhile, the State Treasury mulls over a possibility of staging IPOs of two pharmaceuticals manufacturers, Polfa Pabianice and Polfa Warszawa, although the privatisation path stipulating for a branch investor is also possible. Both companies will compete for a market primacy with the leader that is to be created after the merger of Gedeon Richter and Polpharma due for approved by anti-monopoly watchdog already in Q2. On the wholesale market, PGF remains the leading player. In order to strengthen its position, it created a new company called CEPD. PGF is challenged by its rivals ? Torfarm, Farmacol and others, which have been active when it comes to acquisitions and takeovers. All key players are considering bidding for two last state-owned wholesalers, Cefarm Bialystok and Cefarm Warszawa. |
| Word Count: | 6587 |
| Length: | 12 Pages |
| Document ID: | PL-PharRMay708 |
| Country: | Poland |
| Format: | 
Adobe Acrobat
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?
